Study of Energy Requirements in Critically Ill Newborns
Study Details
Study Description
Brief Summary
OBJECTIVES:
- Determine the total energy expenditure in term and preterm infants in both well and ill states using the doubly labeled water method.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
PROTOCOL OUTLINE: Patients are assigned to one of three groups according to gestational age (24-28 weeks estimated gestational age (EGA) vs 29-34 weeks EGA vs 35 weeks EGA and over) and severity of respiratory illness (need for high frequency ventilation vs stable conventional ventilator settings or extubated within past 24 hours vs no need for mechanical ventilation).
Patients receive water labeled with deuterium and oxygen O 18 by mouth or by gastrostomy tube on days 1 and 7. Urine samples are collected prior to the first dose, 4-6 hours after the first dose, and then every 24 hours until the second dose. All urine is collected for 4-6 hours after the second dose. Samples are analyzed by dual inlet isotope ratio mass spectrometry.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Infants with estimated gestational age (EGA) of at least 24 weeks with respiratory illness who are on high frequency ventilation (HFOV) and meet the following conditions: Appropriate size for gestational age (AGA) No congenital anomalies No medical complications, including seizures and necrotizing enterocolitis
OR
Control infants with EGA of at least 24 weeks Must meet 1 of the following conditions:
Requirement for stable conventional ventilator settings with respiratory index score of less than 2.5 and/or extubated within past 24 hours No requirement for mechanical ventilation Must meet all of the following conditions: AGA No congenital anomalies No medical complications, including seizures and necrotizing enterocolitis No documented sepsis by positive blood culture No supplemental oxygen use (infants 35 weeks EGA and over only)
--Prior/Concurrent Therapy--
HFOV group: Concurrent surfactant, theophylline, or inotrope (vasopressor) therapy allowed
Control group: No concurrent inotrope (vasopressor) therapy
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Indiana University | Indianapolis | Indiana | United States | 46202-5167 |
Sponsors and Collaborators
- National Center for Research Resources (NCRR)
- Indiana University School of Medicine
Investigators
- Study Chair: Catherine A. Leitch, Indiana University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NCRR-M01RR00750-9044
- IU-9703-22